| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 4
Volume 50 Number 3
Volume 50 Number 2
Volume 50 Number 1
Volume 49 Number 6
Volume 49 Number 5
Earlier issues
Volume 49 Number 3


Research articles

ScienceAsia 50 (2024):ID 2024076 1-9 |doi: 10.2306/scienceasia1513-1874.2024.076


11β- hydroxysteroid dehydrogenase type 1 selective inhibitor alleviates insulin resistance and non-alcoholic fatty liver disease in db/db mice


Wen-wen Qia, Yong Liub, Peng-fei Liuc, Mei Yib, Chao Zhangb, Shuang Zhangd, Li-Yong Zhonga,*

 
ABSTRACT:     Non-alcoholic fatty liver disease, often linked to insulin resistance, is associated with increased expression of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1) in liver tissue. We here assessed the effects of the 11?-HSD1 inhibitor BVT.2733 on non-alcoholic fatty liver disease and its underlying mechanisms. Mice were divided into three groups: control, db/db, and db/db +BVT.2733. After 4 weeks, serological testing was conducted, and glucose tolerance and insulin sensitivity were assessed. The severity of non-alcoholic fatty liver disease was evaluated using B-ultrasound, Hematoxylin and Eosin staining, and Oil Red O staining. Liver corticosterone levels were measured using enzyme-linked immunosorbent assay. Liver expression of 11?-HSD1, Phosphatidylinositol 3-kinase (PI3K) -Serine-Threonine kinase (AKT)-Mammalian target of rapamycin (mTOR) signaling pathway-related proteins, and autophagy-related proteins were analyzed by western blot. The results indicated that the leptin receptor-deficient mice db/db showed significant glucolipid metabolism disorder, insulin resistance, and increased non-alcoholic fatty liver disease severity, compared with the control group. BVT.2733 treatment ameliorated these conditions. Specifically, BVT.2733 downregulated liver 11?-HSD1 expression, resulting in reduced liver corticosterone levels. Additionally, BVT.2733 enhanced hepatocyte autophagy, activated the PI3K-AKT signaling pathway and inhibited the mTOR signaling pathway. These findings suggest that BVT.2733 not only improves glucolipid metabolism and insulin resistance but also mitigates non-alcoholic fatty liver disease, in leptin receptor-deficient mice db/db. The underlying mechanism likely involves decreased liver corticosterone levels and enhanced hepatocyte autophagy, mediated by the PI3K-AKT and mTOR signaling pathways.

Download PDF

0 Downloads 65 Views


a Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070 China
b Department of Ultrasound, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038 China
c Department of Anesthesiology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038 China
d Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038 China

* Corresponding author, E-mail: zhongliyong@bjtth.org

Received 27 May 2023, Accepted 6 Jul 2024